An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease

Journal of Neural Transmission

Volumn 121, Issue 3, 2014, Pages 275-281

  Hatano, Taku ^a   Hattori, Nobutaka ^a   Kawanabe, Tadaaki ^b   Terayama, Yasuo ^c   Suzuki, Norihiro ^d   Iwasaki, Yasuo ^e   Fujioka, Toshiki ^f  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^f TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

Author keywords

Neuropsychiatric inventory (NPI); Neuropsychiatric symptoms; Parkinson's disease; Yokukansan (YKS)

Indexed keywords

KAMPO; POTASSIUM; UNCLASSIFIED DRUG; YOKUKANSAN;

ABERRANT MOTOR ACTIVITY; AGED; AGITATION; ANXIETY; APATHY; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; DELUSION; DEPRESSION; DISEASE COURSE; DISINHIBITION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EUPHORIA; FEMALE; HALLUCINATION; HOEHN AND YAHR SCALE; HUMAN; HYPOKALEMIA; IRRITABILITY; LISTLESSNESS; MALE; MENTAL DISEASE; MOTOR PERFORMANCE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEGATIVE SYNDROME; NEUROPSYCHIATRIC INVENTORY; PARKINSON DISEASE; POSITIVE SYNDROME; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 84896727628     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1105-y     Document Type: Article

References (28)

1. Aarsland D, Larsen JP, Lim NG et al (1999) Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 67(4):492-496
2. Ballanger B, Strafella AP, van Eimeren T et al (2010) Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 67(4):416-421
3. Brandstädter D, Oertel WH (2002) Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 58(1):160-161
4. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5(3):235-245
5. Conn JW, Rovner DR, Cohen EL (1968) Licorice-induced pseudoaldosteronism. Hypertension, hypokalemia, aldosteronopenia, and suppressed plasma renin activity. JAMA 205(7):492-496
6. Cummings JL, Mega M, Gray K et al (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12):2308-2314
7. Egashira N, Iwasaki K, Ishibashi A et al (2008) Repeated administration of yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 32(6):1516-1520
8. Fahn S, Elton RL, UPDRS Program Members (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson's disease, vol 2. Macmillan Healthcare Information, Florham Park, pp 153-163 (293-304)
9. Fernandez HH, Friedman JH, Jacques C et al (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 14(3):484-487
10. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189-198
11. Fujioka T, Kawabe K, Kiyozuka T et al (2009) The effect of yokukansan on hallucinations in the patients with Parkinson disease treated with l-Dopa. Neurol Ther 26(1):55-59
12. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427-442
13. Iwasaki K, Satoh-Nakagawa T, Maruyama M et al (2005a) A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 66(2):248-252
14. Iwasaki K, Maruyama M, Tomita N et al (2005b) Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. J Clin Psychiatry 66(12):1612-1613
15. Iwasaki K, Kosaka K, Mori H et al (2011) Open label trial to evaluate the efficacy and safety of yokukansan, a traditional Asian medicine, in dementia with Lewy bodies. J Am Geriatr Soc 59(5):936-938
16. Iwasaki K, Kosaka K, Mori H et al (2012) Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine. Psychogeriatrics 12(4):235-241
17. Kawakami Z, Ikarashi Y, Kase Y (2010) Glycyrrhizin and its metabolite 18 beta-glycyrrhetinic acid in glycyrrhiza, a constituent herb of yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes. Eur J Pharmacol 626(2-3):154-158
18. Kawakami Z, Kanno H, Ikarashi Y et al (2011a) Yokukansan, a kampo medicine, protects against glutamate cytotoxicity due to oxidative stress in PC12 cells. J Ethnopharmacol 134(1):74-81
19. Kawakami Z, Ikarashi Y, Kase Y (2011b) Isoliquiritigenin is a novel NMDA receptor antagonist in Kampo medicine yokukansan. Cell Mol Neurobiol 31(8):1203-1212
20. Kawanabe T, Yoritaka A, Shimura H et al (2010) Successful treatment with yokukansan for behavioral and psychological symptoms of Parkinsonian dementia. Prog Neuropsychopharmacol Biol Psychiatry 34(2):284-287
21. Merims D, Balas M, Peretz C et al (2006) Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 29(6):331-337
22. Mizoguchi K, Tanaka Y, Tabira T (2010) Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex. J Ethnopharmacol 127(1):70-76
23. Papapetropoulos S, Mash DC (2005) Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol 252(7):753-764
24. Pollak P, Tison F, Rascol O et al (2004) Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75(5):689-695
25. Seppi K, Weintraub D, Coelho M et al (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 26:S42-S80
26. Takeda A, Tamano H, Itoh H et al (2008) Attenuation of abnormal glutamate release in zinc deficiency by zinc and yokukansan. Neurochem Int 53(6-8):230-235
27. Terawaki K, Ikarashi Y, Sekiguchi K et al (2010) Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells. J Ethnopharmacol 127(2):306-312
28. Weintraub D, Stern MB (2005) Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 13(10):844-851